Prehospital Aspirin Dosing for Suspected Acute Coronary Syndrome
Administer 162-325 mg of non-enteric-coated, chewable aspirin immediately in the prehospital setting for adults with suspected acute coronary syndrome, unless there is a documented aspirin allergy or active gastrointestinal bleeding. 1, 2, 3, 4, 5, 6
Recommended Dose
The loading dose should be:
- 162-325 mg of non-enteric-coated aspirin
- Must be chewed (not swallowed whole) for rapid buccal absorption 1, 7
- Administered as soon as possible after symptom recognition 1, 4
The evidence consistently supports this dose range across both STEMI and NSTE-ACS presentations. The most recent 2025 ACC/AHA guideline reaffirms the 162-325 mg loading dose 6, maintaining consistency with prior recommendations dating back over two decades. Non-enteric-coated formulations are critical because enteric coating delays and reduces absorption 2, 3.
Timing of Administration
Aspirin should be given at first medical contact, which can occur at multiple points:
- By 9-1-1 dispatchers: It is reasonable for dispatchers to instruct patients without aspirin allergy to chew aspirin (160-325 mg) while awaiting EMS arrival 8, 5, 7
- By EMS providers: Prehospital EMS should administer aspirin immediately upon patient contact 1, 5, 7
- Before hospital arrival: The earlier aspirin is given, the better the outcomes 1, 4
Absolute Contraindications
Do not administer aspirin if:
- Known aspirin allergy or hypersensitivity (including history of hives, facial swelling, asthma/wheezing, or anaphylaxis) 2, 3, 4, 9
- Active gastrointestinal bleeding 8, 5
- Major gastrointestinal intolerance documented in medical history 2, 3
For patients with true aspirin allergy, a P2Y12 inhibitor (clopidogrel 300-600 mg loading dose) should be substituted 2, 3. Aspirin desensitization is preferred when feasible to allow dual antiplatelet therapy 6.
Clinical Pitfalls to Avoid
Do not use enteric-coated aspirin for initial loading - this is a common error that significantly delays therapeutic effect 1, 2, 3. The guidelines explicitly state that although some trials used enteric-coated formulations, non-enteric-coated aspirin provides more rapid buccal absorption.
Do not delay aspirin for diagnostic confirmation - aspirin should be given based on clinical suspicion of ACS, not after ECG or biomarker confirmation 4, 6. The 2017 performance measures specify administration "at arrival" for suspected ACS 4.
Do not withhold aspirin due to concerns about bleeding in appropriate candidates - the mortality benefit in ACS far outweighs bleeding risk in patients without absolute contraindications 1, 4. However, patients ≥60 years old, those with history of ulcers, or those taking anticoagulants require careful consideration 9.
Evidence Strength
This recommendation carries Class I, Level of Evidence A across multiple guidelines 1, 2, 3, 4, 6, representing the highest level of evidence and strongest recommendation possible. The ISIS-2 trial demonstrated a 23% relative risk reduction in 5-week vascular mortality with aspirin in STEMI 4, and subsequent trials have consistently shown benefit across the ACS spectrum.
The consistency of this recommendation from 2004 through 2025 guidelines reflects robust, unchanging evidence for this intervention 1, 3, 7, 6.